Equities

ReNeuron Group PLC

ReNeuron Group PLC

Actions
  • Price (EUR)0.034
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-65.48%
  • Beta--
Data delayed at least 15 minutes, as of Feb 05 2024 08:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)249.00k
  • Net income in GBP-5.07m
  • Incorporated2005
  • Employees34.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttps://www.reneuron.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.